Overview

A Study to Evaluate the Effects of Azilsartan on Coronary Artery Plaque in Essential Hypertensive Patients With Stable Angina and Dyslipidemia.

Status:
Withdrawn

Trial end date:
2016-04-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the effects of oral azilsartan once daily for 32 weeks on coronary artery plaque in essential hypertensive patients with stable angina and dyslipidemia.

Phase:

Phase 4

Details

Lead Sponsor:

Takeda

Treatments:

Azilsartan medoxomil